Morgan Stanley Lyell Immunopharma, Inc. Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Morgan Stanley holds 866,403 shares of LYEL stock, worth $9.16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

866,403

Previous 1,214,287 28.65%

Holding current value

$9.16 Million

Previous $777,000 39.9%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$0.48 - $0.74 $166,984 - $257,434	-347,884 Reduced 28.65%	866,403 $467,000
Q4 2024 Feb 14, 2025	SELL	$0.59 - $1.48 $303,036 - $760,159	-513,621 Reduced 29.73%	1,214,287 $777,000
Q3 2024 May 14, 2025	BUY	$1.13 - $1.88 $1.44 Million - $2.4 Million	1,277,148 Added 283.33%	1,727,908 $2.38 Million
Q3 2024 Nov 14, 2024	BUY	$1.13 - $1.88 $1.44 Million - $2.4 Million	1,277,148 Added 283.33%	1,727,908 $2.38 Million
Q2 2024 May 14, 2025	SELL	$1.3 - $3.01 $992,585 - $2.3 Million	-763,527 Reduced 62.88%	450,760 $653,000
Q2 2024 Oct 17, 2024	SELL	$1.3 - $3.01 $122,989 - $284,767	-94,607 Reduced 17.35%	450,760 $653,000
Q2 2024 Aug 14, 2024	SELL	$1.3 - $3.01 $122,989 - $284,767	-94,607 Reduced 17.35%	450,760 $653,000
Q1 2024 Oct 17, 2024	BUY	$1.71 - $3.07 $161,777 - $290,443	94,607 Added 20.99%	545,367 $1.22 Million
Q1 2024 Aug 16, 2024	SELL	$1.71 - $3.07 $3,813 - $6,846	-2,230 Reduced 0.41%	545,367 $1.22 Million
Q1 2024 May 15, 2024	SELL	$1.71 - $3.07 $3,813 - $6,846	-2,230 Reduced 0.41%	545,367 $1.22 Million
Q4 2023 Aug 16, 2024	BUY	$1.39 - $2.35 $134,603 - $227,566	96,837 Added 21.48%	547,597 $1.06 Million
Q4 2023 Feb 13, 2024	BUY	$1.39 - $2.35 $406,793 - $687,743	292,657 Added 114.79%	547,597 $1.06 Million
Q3 2023 Nov 15, 2023	SELL	$1.45 - $3.35 $140,033 - $323,526	-96,575 Reduced 27.47%	254,940 $374,000
Q2 2023 Aug 14, 2023	BUY	$1.89 - $3.86 $200,039 - $408,546	105,841 Added 43.08%	351,515 $1.12 Million
Q1 2023 May 15, 2023	BUY	$1.97 - $3.58 $52,768 - $95,893	26,786 Added 12.24%	245,674 $579,000
Q4 2022 Feb 14, 2023	SELL	$2.78 - $8.09 $545,438 - $1.59 Million	-196,201 Reduced 47.27%	218,888 $759,000
Q3 2022 Nov 14, 2022	BUY	$5.54 - $8.27 $1.1 Million - $1.64 Million	198,195 Added 91.38%	415,089 $3.04 Million
Q2 2022 Oct 27, 2022	SELL	$3.68 - $6.8 $519,417 - $959,792	-141,146 Reduced 39.42%	216,894 $1.42 Million
Q2 2022 Aug 15, 2022	SELL	$3.68 - $6.8 $519,417 - $959,792	-141,146 Reduced 39.42%	216,894 $1.42 Million
Q1 2022 Oct 27, 2022	BUY	$5.05 - $7.7 $712,787 - $1.09 Million	141,146 Added 65.08%	358,040 $1.81 Million
Q1 2022 May 13, 2022	SELL	$5.05 - $7.7 $3.25 Million - $4.96 Million	-643,704 Reduced 64.26%	358,040 $1.81 Million
Q4 2021 Feb 14, 2022	BUY	$7.13 - $15.19 $3.3 Million - $7.03 Million	462,743 Added 85.85%	1,001,744 $7.75 Million
Q3 2021 Nov 15, 2021	BUY	$11.0 - $17.95 $5.93 Million - $9.68 Million	539,001 New	539,001 $7.98 Million

Others Institutions Holding LYEL

# of Institutions

Shares Held

109M

Call Options Held

2.9K

Put Options Held

View Full List

About Lyell Immunopharma, Inc.

Ticker LYEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 247,824,992
Market Cap $2.62B
Description
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...

More about LYEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account